Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's ...

Moderna President Stephen Hoge says the company remains on track for its longtime goal of reaching cash breakeven by 2028.

The stock market showed choppy, mixed weekly action. But Robinhood, Sandisk, AMD and Moderna rallied into buy areas.

But what has the stock done for shareholders lately? How has it done over the past five years? Not so great. It has averaged annual losses over that period -- enough to turn a single $10,000 ...

The biotech is entering a new era.

After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of ...

Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be.

The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before investors pulled back.

After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the biotech company a much-needed win.

That came after Moderna and Merck announced their personalized cancer vaccine helped cut the recurrence of melanoma—a form of ...

One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a ...

Moderna (MRNA) closed at $146.69 in the latest trading session, marking a +1.89% move from the prior day. The stock ...